Core Insights - IMAC Holdings, Inc. has appointed Dr. Peter Beitsch and Dr. Matthew Schwartz to its Board of Directors, effective June 26, 2024, to enhance its position in proteomics and precision medicine [1][4] Group 1: Board Appointments - Dr. Matthew Schwartz has over 18 years of experience in cancer patient care using radiotherapy and precision oncology, currently serving as a Radiation Oncologist [2] - Dr. Peter Beitsch has a strong background in surgical oncology and genomics, actively involved in breast cancer research, and is a Co-Founder of Targeted Medical Education [3] Group 2: Strategic Importance - The expertise of Dr. Schwartz and Dr. Beitsch is expected to guide the company's strategic initiatives and enhance its research capabilities in proteomics [3] - The appointments are seen as pivotal for steering the company towards innovation and success in the field of proteomics [4] Group 3: Company Overview - IMAC, through its subsidiary Ignite Proteomics, aims to revolutionize proteomics research with innovative technologies, including Reverse Phase Protein Arrays (RPPA) [4]
IMAC Holdings, Inc. Appoints Dr. Matthew Schwartz and Dr. Peter Beitsch to Board of Directors